CN105664152A

CN105664152A - Double-strand oligonucleotide-epsilon-polylysine compound with immune regulation function and preparation and use method of double-strand oligonucleotide-epsilon-polylysine compound

Info

Publication number: CN105664152A
Application number: CN201610056797.6A
Authority: CN
Inventors: 苏文全
Original assignee: Individual
Current assignee: Beijing Jiayi Weike Biotechnology Co.,Ltd.
Priority date: 2016-01-27
Filing date: 2016-01-27
Publication date: 2016-06-15
Anticipated expiration: 2036-01-27
Also published as: CN105664152B

Abstract

The invention provides a double-strand oligonucleotide-epsilon-polylysine compound with an immune regulation function and a preparation and use method of the double-strand oligonucleotide-epsilon-polylysine compound and also provides immunogen composition with functions of triggering immunoenhancement reaction and changing the immunoreaction type and a preparation and use method of the immunogen composition. The immunogen composition comprises the double-strand oligonucleotide-epsilon-polylysine compound and an antigen. The compound contains a compound formed through composition of double-stranded polynucleotide, a cation epsilon-polylysine and metal cations. The compound has the pharmacological activity of immunoregulation. The preparation process of the compound is simple. The compound has good water solubility and a bio-enzyme degradation resisting function. The immunogen composition can trigger the immunoenhancement reaction and change the immunoreaction type.

Description

A kind of double stranded polynucleotide epsilon-polylysine complex with immunoregulation effect and preparation using method thereof

Technical field

The present invention relates to field of medicaments, the present invention provides a kind of double stranded polynucleotide ε polylysine complex with immunoregulation effect and preparation using method thereof specifically. The present invention also provides a kind of and has the immunogenic composition causing enhancing immunoreation and change immunoreation type action and preparation using method thereof.

Background technology

One, double stranded polynucleotide: double stranded polynucleotide or derivatives thereof has multiple pharmacologically active, source is natural extract or synthetic. The double stranded polynucleotide of synthetic such as polyinosini (polyI:C) can produce interferon in inductor, protects cells from viral infection, has curative effects such as preventing and treating viral disease; The viral double-stranded RNA that the double stranded polynucleotide of natural extract such as Reoviridae extracts has antiviral, antitumor isoreactivity.

Polyinosini (PolyIC, PIC) is the double-stranded products after the poly-inosine monophosphate, IMP (PolyI) of synthetic and poly-cytidylic acid (PolyC) pairing, is a kind of efficiently interferon inducer. But owing to PIC is prone to, by the nuclease hydrolysis in people and primate serum, limit Clinical practice.

Polyinosini is mainly used in prevention and treatment viral infection, such as influenza, viral hepatitis, phlyctenular conjunctivitis. Also the auxiliary therapy in tumor is tried out. A few patients has a transient low grade fever, accidental weak, xerostomia, feels sick.

Two, ε polylysine

Within 1977, Japanese scholars S.Shima and H.Sakai is in the process of screening from microorganism, find that a strain actinomycetes No.346 can produce a large amount of and stable Dragendo～Positive (being abbreviated as DP) materials, by to the analysis of acid hydrolysis products and structural analysis, confirm that this DP material is a kind of homotype monomer-polymer containing 25 30 lysine residues, be called ε poly-D-lysine (ε PL).

ε polylysine has good sterilizing ability and heat stability. The mechanism of action of ε polylysine is mainly manifested in following 3 aspects:

(1) cell wall and cell membrane system are acted on;

(2) hereditary material or hereditary particle structure are acted on;

(3) enzyme or functional protein are acted on.

ε polylysine is rich in cation, there is strong electrostatic force with the material with anion and biomembrane is had good penetration power, can be used for the carrier of some drugs based on this characteristic poly-D-lysine, be therefore used widely in medical treatment and pharmacy.ε polylysine is polymerized with ammonia methylpurine (treating the medicine of leukemia, tumor), can improve the curative effect of medicine.

Three, the type of specific immunity

Specific immunity (specificimmunity) is also known as acquired immunity or adaptive immunity, and this immunity is just for a kind of cause of disease. It is that adaptive immune makes body obtain opposing infection ability through acquired infection (recovering or asymptomatic infection) or artificial prophylactic immunization (vaccine, vaccine, toxoid, immunoglobulin etc.). It is usually (immunoglobulin, the immunological lymphocyte) that just formed after the antigenic substances such as microorganism stimulate, and specific reaction can be played with this antigen.

The immunity of specific immunity cell type:

T cell is to participate in the lymphocyte of cellular immunization, after being subject to antigenic stimulus, is converted into primed lymphocyte, and shows specific immune response, and immunne response is transmitted only by primed lymphocyte, therefore claims cellular immunization. Immunologic process is by sensing, reaction, effect three phases, when stage of reaction primed lymphocyte is again with antigen contact, just multiple lymphokine (transfer factor, migration inhibitory factor are discharged, activity factor, skin reactive factor, lymph poison, interferon), with macrophage, killer T cell is collaborative plays immunologic function. Cellular immunization is mainly through infection; Immune surveillance; Transplant rejection; Participation delayed allergy is worked. Secondly helper T lymphocyte and suppressor T lymphocyte also participate in the adjustment of humoral immunization.

Specific immunity type humoral immunization:

B cell is the sensitization B cell participating in humoral immunization. Being converted into plasma cell, synthetic immunoglobulin under antigenic stimulus, the immunoglobulin being combined with target antigen is antibody. Immunoglobulin (Immunoglobulin, Ig) is divided into five classes.

1. IgG is the immunoglobulin that in serum, content is maximum, uniquely by the antibody of Placenta Hominis, can have the characteristics such as antibacterial, antiviral, antitoxin, toxic product rises neutralization, precipitation, complement fixation, and gamma globulin used is IgG clinically.

2. IgM is the immunoglobulin that molecular weight is maximum, is the antibody synthesized at first in ontogeny, because it is a kind of macroglobulin, therefore can not pass through Placenta Hominis. Serum detects specific IgM, as the mark of infectious disease early diagnosis, discloses and recently infect or persistent infection, there is conditioning, sterilization, agglutination.

3. IgA has amphitypy namely to secrete and serotype. Secretory IgA is present in nose, bronchial secretion, saliva, gastro-intestinal Fluid and first Ruzhong. Its effect is that pathogen adheres to mucomembranous surface, stops diffusion. Serotype IgA, immunologic function still imperfectly understands. 4. there is immunoglobulin the latest in IgE, can sensitization mastocyte and basophilic granulocyte, so as to retting conditions, discharge histamine. Parasitic infection, SERUM IgE content increases.

5. its immunologic function of IgD is unclear.

Also has the class cell without T Yu bone-marrow-derived lymphocyte mark, there is Antibody-dependent cell cytotoxicity effect and can kill the target cell that specific antibody combines, also known as killing cell (Killercell), it is called for short K cell, participate in ADCC effect, at antiviral, in anti-parasitic-infectious, act the effect of killing. Another class has the cell of NKT effect, is called natural killer cell (naturalkillercell) i.e. NK cell. When killing target cell, it is not necessary to antibody participates in complement.

Specific immunity forming process

Under antigenic stimulus, the specific immune response of body generally can be divided into sensing, reaction and 3 stages of effect.It is divided into three phases: 1 phase of sensitization is the stage that antigen processes, presents and identify;

2. the stage of reaction is B cell, T cell proliferation and differentiation, and the stage that memory cell is formed;

3. the effective stage is the stage that effector T cell, antibody and lymphokine play immunological effect.

If some pathogen breaches first and second defence line, namely enter human body growth and breeding, cause infection. What have has symptom, it is simply that ill; What have does not have symptom, is called inapparent infection. Whether any situation, body all experienced by the process once struggled against with pathogen, and this identification being specifically designed for a certain pathogen (antigen) and killing action are called specific immunity. Bacillus typhi is had lasting immunity by the people that such as must cross typhoid, and that is because Bacillus typhi stimulates body to produce immunne response, adds the phagocytic function of macrophage, also produces the antibody of anti-Bacillus typhi in vivo simultaneously. The immune system of human body can be got off the feature of Bacillus typhi this " enemy " long-term " memory " again, if there being Bacillus typhi to enter again, will quickly be identified, being destroyed.

The immunocyte that can carry out immunne response has a variety of, it is most important that lymphocyte. It is divided into again two kinds. The maturation process during fetal growth of two kinds of cells is different, and one is to reach maturity in thymus, is called T lymphocyte, is that fully-developed is bone-marrow-derived lymphocyte in bone marrow.

The macrophage with ink-uptaking test is also a kind of important immunocyte, and it has the effect of " processing factory ", namely after macrophage phagocytic foreign body (such as antibacterial, tumor cell etc.), is processed foreign body processing. Foreign body (antigen) after process just with T lymphocyte and bone-marrow-derived lymphocyte generation immunoreation, itself also can directly kill foreign body or produce cytokine participate in immunoreation.

After bone-marrow-derived lymphocyte is stimulated by pathogen, cause a series of change, it is eventually converted into the plasma cell for antibody can be produced, produced antibody carrys out eliminating pathogen by various modes, as dissolved pathogen, neutralizing the toxin that pathogen produces, coagulation pathogen makes larger particles and eats elimination by phagocyte. The antibody that plasma cell produces is present in blood and the body fluid of body, and this immunoreation is known as humoral immunization.

Pathogen after treatment causes a series of change too, is eventually converted into the primed lymphocyte that can discharge lymphokine after stimulating T lymphocyte. Lymphokine kind is a lot, and effect also and differs, and they are actively participating in immunoreation, and this immunoreation is commonly referred to cellular immunization. Humoral immunization and cellular immunization are not therebetween isolated, and they complement each other, and cooperate with each other, and jointly play immunization.

Specific immunity causes and strengthens immunological adjuvant

Also known as nonspecific immunity proliferant agent. Itself do not have antigenicity, but synantigen is expelled to together or in advance in body and can strengthen immunogenicity (see antigen) or change immunoreation type.

Kind is a lot, there is no unified sorting technique at present, and conventional adjuvant can be divided into 4 classes: inorganic adjuvant, such as aluminium hydroxide, Alumen etc.; Organic adjuvant, microorganism and product thereof such as mycobacteria (tubercule bacillus, bacillus calmette-guerin vaccine), bacillus pumilis, bordetella pertussis, endotoxin, bacterial extract (muramyldipeptide) etc.; Synthetic adjuvant, such as the double stranded polynucleotide (double-strand polyadenylic acid, uridylic acid) of synthetic, levamisole, inosine pranobex etc.;Oil preparation, such as Fei Shi adjuvant, adjuvant 65, mineral oil, plant wet goods. Freund adjuvant is the most frequently used in laboratory animal at present, can be divided into again incomplete Freund's adjuvant and Freund's complete adjuvant two kinds. Freund's incomplete adjuvant is that oil preparation (paraffin oil or vegetable oil) mixes mutually with emulsifying agent (lanoline or tween (Tween) 80), when it mixes with antigen again, water in oil emulsion, can be used for inoculation. Freund's incomplete adjuvant adds dead mycobacteria, namely becomes Freund's complete adjuvant. The immune intensity of Freund's complete adjuvant is more than Freund's incomplete adjuvant. This adjuvant is mainly used in zoopery, is unsuitable for the mankind and uses. And after animal multiple injection, also often can there is adjuvant disease.

The biological agent of immunological adjuvant includes:

(1), after antigenic substance mixing adjuvant injects body, change the physical behavior of antigen, antigenic substance can be made to discharge lentamente, extend the action time of antigen;

(2) after adjuvant has adsorbed antigen, add the surface area of antigen, make antigen be prone to by macrophage phagocytic;

(3) adjuvant can stimulate the phagocyte process to antigen;

(4) adjuvant can promote the contact between lymphocyte, strengthens the effect of helper T cell;

(5) division and the plasma cell that can stimulate primed lymphocyte produce antibody. Therefore the effect of immunological adjuvant can make non-immunogenicity material become effective immunogen;

(6) first and secondary immune response the antibody of body can be improved and drip change;

(7) change the generation type of antibody and produce delayed allergy, and making it strengthen.

The patented invention application documents that publication number is CN101166559B disclose a kind of immunogenic substances comprising the adjuvant based on poly I: C; The patented invention application documents that publication number is CN101124014B disclose a kind of mucosal immunity material containing the adjuvant based on poly I: C. The adjunvant composition that these two patents use comprises polyinosini, antibiotic and metal cation. The aminoglycoside antibiotics molecular weight that it adopts is much smaller than ε polylysine, and the ability of the double stranded polynucleotide complex antibiont enzyme water decomposition therefore formed is lower than double stranded polynucleotide ε polylysine complex; Simultaneously because vaccine is mainly used in healthy population, its existing kanamycin has latent lesion auditory nerve, causes deaf risk, and the use of kanamycin easily causes abuse of antibiotics, produce the problems such as drug-resistant bacteria.

The double stranded polynucleotide of anion or double stranded polynucleotide derivant are in vivo easily by the nuclease hydrolysis in people and primate serum, and action time is short, limits Clinical practice. At present, containing kanamycin as cationic stabilized agent in Polynucleotide class medicine Polyinosinic injection, and the use of kanamycin easily causes the problems such as antibiotic remains.

1975, Levy etc. studied and makes PICLC, i.e. the compound of PIC and polylysine and carboxymethyl cellulose, and this compound can resist enzyme hydrolysis, induces out the interferon much higher compared with PIC in people and primate. But PICLC toxic and side effects is serious, on human body, treat 9 example Lymphocytic leukemias with PICLC, have a fever 100%, myalgia 50%, hypotension 50%; Having treated again 7 multiple myelomas and 5 example larynx papillomatosiss, side effect is moderate fever, and moderate hypotension, leukocyte is decreased obviously and myalgia etc.

Polylysine used in reported in literature is the α type polylysine of the macromolecule of chemosynthesis, amido link between its lysine residue is to be formed by alpha-amido and α-carboxyl condensation, and it is poorer and toxic than ε polylysine bacteriostatic activity that research also demonstrates α polylysine.

1969; the Chinese Academy of Sciences cooperates with units concerned and creatively employs new pharmaceutical formulation; develop the polyinosini complex formulation made new advances; namely on PIC basis, add the kanamycin sulfate containing many amidos cation; to protect duplex structure not by nuclease fast hydrolyzing; keep good stability; due effect can be played; due to kanamycin sulfate molecular weight ratio up to several ten thousand or the polylysine of hundreds of thousands molecular weight much smaller; so side reaction is much lower, but the use of kanamycin easily causes the problems such as antibiotic remains.

In order to overcome drawbacks described above, the vertical topic of special decision works out a kind of double stranded polynucleotide ε polylysine complex with immunoregulation effect and preparation using method thereof. This project also provides a kind of and has the immunogenic composition causing enhancing immunoreation and change immunoreation type action and preparation using method thereof.

Summary of the invention

The present invention provides a kind of double stranded polynucleotide ε polylysine complex with immunoregulation effect and preparation using method thereof. The present invention also provides a kind of and has the immunogenic composition causing enhancing immunoreation and change immunoreation type action and preparation using method thereof, comprises this double stranded polynucleotide ε polylysine complex and antigen (such as these two kinds of compositions are positioned at a vaccine). The double stranded polynucleotide ε polylysine complex of what it was described have immunoregulation effect contains the complex that double stranded polynucleotide is composited mutually with cation ε polylysine and metal cation. The purpose of the present invention has the double stranded polynucleotide ε polylysine complex of immunoregulation effect and has good water solublity and antibiont enzyme degradation; Have and cause the immunogenic composition strengthening immunoreation and change immunoreation type action can cause enhancing immunoreation and change immunoreation type. The physicochemical property of this double stranded polynucleotide ε polylysine complex is also defined by the present invention, including complex components proportioning, pH value, concentration.

Advantages of the present invention and effect are in that the preparation technology of this complex is simple; Introduce ε polylysine formation double stranded polynucleotide ε polylysine complex and have good hydrophilic; The form of double stranded polynucleotide and the mutual compound of cation ε polylysine makes its double stranded polynucleotide ε polylysine complex have higher antibiont enzyme degradation than simple double stranded polynucleotide; The ε polylysine introduced contains 25 30 lysine residues, and molecular weight is moderate, and avoids that α polylysine is poisonous and active low shortcoming, it is adaptable to the compound of double stranded polynucleotide; Introduce metal cation and further increase complex immunoregulatory activity. The immunoregulatory pharmacologically active that such complex medicine has, can be used for human drugs and veterinary medicine field; Such complex and the immunogenic composition of antigen thing composition can be used for preventing micro-, the treatment purposes such as biological infection, antitumor.

It is an object of the invention to provide a kind of double stranded polynucleotide ε polylysine complex with immunoregulation effect and preparation using method thereof. The present invention also provides a kind of and has the immunogenic composition causing enhancing immunoreation and change immunoreation type action and preparation using method thereof, it is characterised in that

1. there is a double stranded polynucleotide ε polylysine complex for immunoregulation effect, it is characterized in that containing the complex that double stranded polynucleotide is composited mutually with cation ε polylysine and metal cation.

2. the double stranded polynucleotide ε polylysine complex with immunoregulation effect as described in 1, wherein double stranded polynucleotide refers to the double stranded polynucleotide or derivatives thereof of anion, and source is natural extract or synthetic. Natural extract double stranded polynucleotide derives from the nucleic acid extractive of reovirus coe virus, comprises infections chicken cloacal bursa virus RNA, rotavirus RNA, ovine blue tongue viral RNA, African horse sickness virus RNA; The double stranded polynucleotide of synthetic comprises polyinosini; The final concentration of 1.0g 10g/L of double stranded polynucleotide.

3. the double stranded polynucleotide ε polylysine complex with immunoregulation effect as described in 1, its cationic ε polylysine refers to the cationic ε amino homotype monomer-polymer containing 25 30 lysine residues; The cationic charge number that the preferred proportion of double stranded polynucleotide and ε polylysine is the anionic charge number that has of the phosphate radical of double stranded polynucleotide to be had with the amino of ε polylysine is than for 1:1; Its metal cation is Ca²⁺、Zn²⁺、Mg²⁺、Mn²⁺, and its metal ion is the form of soluble metallic salt, final concentration of 0.2mmol 4mmol/L; The preferred pH scope of its complex solution is 7.0 8.0.

4. the double stranded polynucleotide as described in 3, is characterized in that preferred final concentration of 1.0g/L; The final concentration of 0.383g/L of corresponding ε polylysine; Corresponding metal cation is CaCl₂, final concentration of 0.4mmol/L; Pharmaceutical preparation solvent for use is the PBS of 0.01mol/L, pH=7.6.

5. the preparation method of the double stranded polynucleotide ε polylysine complex with immunoregulation effect as described in 1, it is by the double stranded polynucleotide or derivatives thereof of anion and cation ε polylysine and the mutual compound of metal cation, and make complex, its operating procedure is as follows:

A. the double stranded polynucleotide or derivatives thereof mother liquor of anion:

The double stranded polynucleotide or derivatives thereof PBS of anion is configured to the solution of concentration 1 20mg/ml, and degerming through the membrane filtration in 0.2 0.45 μm of apertures.

B. cation ε polylysine mother liquor:

Cation ε polylysine PBS is configured to the solution of concentration 1 20mg/ml, and degerming through the membrane filtration in 0.2 0.45 μm of apertures.

C. metal cation solution mother liquor:

Metal cation soluble-salt water for injection is configured to the solution that concentration is 0.1mol/L, and degerming through the membrane filtration in 0.2 0.45 μm of apertures.

D. prepared by double stranded polynucleotide ε polylysine complex: double stranded polynucleotide ε polylysine complex prepares rule: at 4 DEG C, first in the double stranded polynucleotide or derivatives thereof mother solution of anion, drip the ε polylysine mother solution of formula ratio, limit drips, limit is stirred, then the metal cation saline solution mother solution of formula ratio is dripped, limit drips, and limit stirring forms double stranded polynucleotide ε polylysine complex solution. Add PBS, regulate pH value to 7.0 8.0 simultaneously, and complex solution is sub-packed in sealing container by continuous stirring after 12 hours at 4 DEG C, boiling water bath 30 minutes, then in current, it is rapidly decreased to room temperature, makes finally aseptic double stranded polynucleotide ε polylysine complex solution through the membrane filtration in 0.2 0.45 μm of apertures is degerming.

6. the double stranded polynucleotide ε polylysine complex with immunoregulation effect as described in 1 can by a kind of administration in following route of administration in the mankind or animal, this route of administration include intramuscular injection, lumbar injection, intravenous injection, subcutaneous injection, through respiratory tract suction, rectally, vagina administration, oral administration, nose administration, administration through eye, transdermal or intradermal administration.

7. having and cause the immunogenic composition strengthening immunoreation with changing immunoreation type action, it comprises the double stranded polynucleotide ε polylysine complex with immunoregulation effect described in 1 and antigen thing. Wherein antigen thing is artificial antigen, animal antigen, plant antigen, microbial antigen or tumor antigen.

8. having as described in 7 causes the immunogenic composition strengthening immunoreation with changing immunoreation type action, and wherein antigen thing is inactivated rabies virus antigen, and in every milliliter of said composition, inactivated rabies virus antigen valence is not less than 1 iu; Its every milliliter said composition double center chain polynucleotide ε polylysine complex, in contained double stranded polynucleotide, is not less than 0.7mg.

9. having as described in 7 causes the preparation method strengthening immunoreation with the immunogenic composition changing immunoreation type action, is double stranded polynucleotide ε polylysine complex and antigen thing are mutually mixed, and makes compositions.

10. as described in 7 having cause strengthen immunoreation with change immunoreation type action immunogenic composition can by a kind of administration in following route of administration in the mankind or animal, this route of administration include intramuscular injection, lumbar injection, intravenous injection, subcutaneous injection, through respiratory tract suction, rectally, vagina administration, oral administration, nose administration, administration through eye, transdermal or intradermal administration. Below by way of conceptual design and method of testing, the present invention is described.

Complex: refer to the coalition formed by two or more different material. When the characteristic of the compound features chemistry totally different with the character that wherein each one-component has, machinery and physics aspect, these components still remain respective primitive character. Indication double stranded polynucleotide ε polylysine complex of the present invention is the complex being mutually composited with cation ε polylysine and metal cation containing double stranded polynucleotide. Indication immunogenic composition comprises this double stranded polynucleotide ε polylysine complex and antigen (such as these two kinds of compositions are positioned at a vaccine).

We attempt preparing a kind of double stranded polynucleotide ε polylysine complex with immunoregulation effect, wish that namely such complex retains and strengthen immunoregulatory pharmacologically active, the characteristic having further through complex, make it have good water solublity, and there is certain antibiont enzyme hydrolysis effect.

The screening conditions of double stranded polynucleotide are double stranded polynucleotide or the double stranded polynucleotide derivants of anion, namely with the double stranded polynucleotide of negative charge.

For increasing the compactness of double stranded polynucleotide, double stranded polynucleotide ε polylysine complex adds metal cation soluble-salt, such as CaCl₂, its final concentration of 0.2mmol 4mmol/L. Zn²⁺、Mg²⁺、Mn²⁺Bivalent metal ion and Ca²⁺There is similar effect.

The compound of this complex carries out compound mutually on the contrary mainly by the electrically charged character of material institute. The cationic charge number that the preferred proportion of double stranded polynucleotide and ε polylysine is the anionic charge number that has of the phosphate radical of double stranded polynucleotide to be had with the amino of ε polylysine is than for 1:1.

According to the pH value range that human or animal body can be accepted extensively, the preferred pH scope of this complex is 7.0 8.0.

We attempt making complex by meeting the above-mentioned double stranded polynucleotide of screening conditions, cation ε polylysine and metal cation.

For reaching this purpose, the involved double stranded polynucleotide of the present invention and cation ε polylysine can be first be sufficiently mixed with solid forms, add solvent again and carry out compound reaction, can also carrying out compound by solid-liquid form, liquid-liquid form, reactant addition, order of addition, reaction condition can suitably be adjusted.

Therefore, have collected double stranded polynucleotide: the Typical Representative thing of synthetic: polyI:C (sedimentation coefficient >=4S), natural extract Typical Representative thing: infections chicken cloacal bursa virus RNA; Cation ε polylysine; CaCl₂. Then carry out complex by preparation method described in present invention and prepare (every kind of concrete preparation method of complex refers to each embodiment).

The made double stranded polynucleotide ε polylysine complex with immunoregulation effect of each embodiment will detect by following all or part of quality determining method.

1, double stranded polynucleotide ε polylysine complex character checks: clear transparent solutions.

2, double stranded polynucleotide ε polylysine complex undue toxicity detection: by " Chinese Pharmacopoeia " method inspection, mice should be good for and be deposited.

3, double stranded polynucleotide ε polylysine complex nuclease-resistant degradation capability detection:

In independent double stranded polynucleotide, commercially available polyinosini, double stranded polynucleotide ε polylysine complex, it is separately added into RNase (in its reaction system every milliliter containing double stranded polynucleotide 40 μ g, RNase10 μ g), digests in room temperature. Double-spiral structure nucleic acid double chain can be made to be hydrolyzed according to RNase, and produce hyperchromicity, and hydrolysis degree is more big, hyperchromicity principle more very, every 15min detection absorbance at A248nm place, complex group makes blank with the corresponding ε polylysin solution without double stranded polynucleotide.

4, the interferon-induced effect detection of double stranded polynucleotide ε polylysine complex:

Take 15 21 day-old chicks and be randomly divided into three groups, often group 10 (double stranded polynucleotide is that the complex group of bursal disease virus RNA is with chicken 2), one group inject double stranded polynucleotide ε polylysine complex prepared by each embodiment, second group inject commercially available polyinosini, the 3rd group of injection 0.01mol/L PBS solution as a control group. Every chicken presses the injection of 0.01ml/Kg body weight, and interval is injected once for three days again, and injection is taken a blood sample after 12 hours, 36 hours the last time, measures the interferon-alpha content in blood by ELISA method.

5, double stranded polynucleotide ε polylysine complex antiviral effect detection:

Take 9 11gKM system white mice 90, be divided into three groups, with encephalitis b virus (P₃Strain, 6.5logLD50/ml) white mice is attacked in abdominal cavity, 0.3ml/ is only, in infecting latter 12 hours, first group of the white mice PBS of 0.05ml/, the commercially available polyinosini of second group white mice 0.05ml/, double stranded polynucleotide ε polylysine complex subcutaneous injection of the 3rd group white mice 0.05ml/ treat white mice, every day 1 time, continuous 3 times. From counteracting toxic substances day, Continuous Observation 21 days, record mouse death rate.

6, the immunogenic composition result of use detection that double stranded polynucleotide ε polylysine complex and antigen thing are made:

Prepared double stranded polynucleotide ε polylysine complex formulation and inactivated rabies virus antigen are sufficiently mixed in the ratio of 7:3, then bioactivity is carried out by rabies vaccine Determination method (NIH method), with commercially available polyinosini+vaccine for matched group, using the inactivated rabies virus antigen of 0.3ml/ agent as simple vaccine matched group.

The concrete preparation of each double stranded polynucleotide ε polylysine complex and double stranded polynucleotide ε polylysine complex, the relevant quality measurements of immunogenic composition refer to detailed description of the invention.

Detailed description of the invention

Below in conjunction with embodiment, the present invention is described in further detail, it should be understood that the scope of the present invention is not limited to the scope of these embodiments.

Embodiment 1

Prepared by the calcium chloride solution of a, 0.1mol/L:

Weigh anhydrous calcium chloride 1.110g 100ml water for injection to dissolve, and through the degerming calcium chloride solution making 0.1mol/L of membrane filtration in 0.2 μm of aperture.

Prepared by the PBS solution (pH=7.6) of b, 0.01mol/L:

Weigh disodium hydrogen phosphate 0.124g, a hypophosphite monohydrate sodium dihydrogen 0.018g, sodium chloride 0.808g respectively, dissolve with 100ml water for injection after mixing, and through the degerming PBS solution (pH=7.6) making 0.01mol/L of membrane filtration in 0.2 μm of aperture.

Prepared by the PolyIC midbody solution of c, 2mg/ml:

Weigh the PolyC of PolyI, 0.9912g of 1.0088g to add the PBS solution of 400ml respectively and dissolve, merge two liquid, mixing shakes up, add PBS solution to 1000ml, after putting 45 DEG C of water-baths 60 minutes, standby through the degerming PolyIC midbody solution making 2mg/ml of the membrane filtration in 0.45 μm of aperture.

Prepared by the ε polylysin solution of d, 10mg/ml:

The PBS solution weighing ε polylysine 1.000g 100ml is dissolved, and through the degerming ε polylysin solution making 10mg/ml of membrane filtration in 0.45 μm of aperture.

E, pH value regulate liquid to be prepared:

Weighing sodium hydroxide 4.0g 100ml water for injection dissolves, and the membrane filtration through 0.2 μm of aperture makes pH value adjustment liquid.

Prepared by f, PolyIC ε polylysine complex:

It is operated at 4 DEG C, first stirs to limit in the PolyIC midbody solution of 50ml, the ε polylysin solution of limit dropping 3.83ml, stirs to limit in above-mentioned mixed liquor, the calcium chloride solution of limit dropping 0.4ml afterwards. Add PBS to 100ml, regulate liquid with pH value simultaneously and regulate pH to 7.6, and complex solution is sub-packed in sealing container by continuous stirring after 12 hours at 4 DEG C, boiling water bath 30 minutes, then sealing container is put and current are rapidly decreased to room temperature, boiling water bath 30 minutes, then puts sealing container and is rapidly decreased to room temperature in current, makes aseptic PolyIC ε polylysine complex formulation through the membrane filtration in 0.45 μm of aperture is degerming after.

Embodiment 2

Prepared by the calcium chloride solution of a, 0.1mol/L:

Prepared by the PBS solution (pH=7.6) of b, 0.01mol/L:

Prepared by the bursal disease virus RNA solution of c, 2mg/ml:

Bursal disease virus RNA PBS is dissolved, through the degerming solution for standby making 2mg/ml of membrane filtration in 0.45 μm of aperture.

Prepared by the ε polylysin solution of d, 10mg/ml:

E, pH value regulate liquid to be prepared:

Prepared by f, bursal disease virus RNA ε polylysine complex:

It is operated at 4 DEG C, first stirs to limit in the bursal disease virus RNA solution of 0.5ml, while drip the ε polylysin solution of 38 μ l, stir to limit in above-mentioned mixed liquor afterwards, while drip the calcium chloride solution of 4 μ l.Add PBS to 1.0ml, regulate liquid with pH value simultaneously and regulate pH to 7.6, and complex solution is sub-packed in sealing container by continuous stirring after 12 hours at 4 DEG C, boiling water bath 30 minutes, then sealing container is put and current are rapidly decreased to room temperature, after, make aseptic bursal disease virus RNA ε polylysine complex through the membrane filtration in 0.45 μm of aperture is degerming.

Each embodiment double stranded polynucleotide ε polylysine complex quality measurements.

1, double stranded polynucleotide ε polylysine complex character checks:

Result of the test shows, two kinds of double stranded polynucleotide ε polylysine complex character inspections are all qualified.

2, double stranded polynucleotide ε polylysine complex undue toxicity detection:

Group	Check result
		Embodiment 1 complex	Mice all should be good for and be deposited.

Result of the test shows, it is qualified that the double stranded polynucleotide ε polylysine complex undue toxicity of embodiment 1 preparation detects.

3, double stranded polynucleotide ε polylysine complex nuclease-resistant degradation capability detection

Result of the test shows, two kinds of double stranded polynucleotide ε polylysine complex are all strong than simple double stranded polynucleotide, commercially available polyinosini nuclease-resistant degradation capability.

4, the interferon-induced effect detection of double stranded polynucleotide ε polylysine complex

Result of the test shows, two kinds of double stranded polynucleotide ε polylysine complex all have good interferon-induced effect.

5, double stranded polynucleotide ε polylysine complex antiviral effect detection

Group	Mouse death rate (dead number of elements/experiment number of elements)	Mouse death rate
			Embodiment 1 complex	10/30	33.3%
Commercially available polyinosini matched group	12/30	40%
			PBS	23/30	76.7%

Result of the test shows, selected double stranded polynucleotide ε polylysine complex group therapeutic effect is better than commercially available polyinosini group and PBS control group.

6, the immunogenic composition result of use detection that double stranded polynucleotide ε polylysine complex and antigen thing are made

Vaccine lot number	Vaccine valence (IU/ml)
		Embodiment 1 complex+vaccine	6.6
Commercially available polyinosini+vaccine	5.6
		Without compound vaccine	1.3

Result of the test shows, the immunogenic composition that selected double stranded polynucleotide ε polylysine complex and inactivated rabies virus antigen are made, and on the basis of the 70% vaccine antigen amount of saving, vaccine valence is higher than commercially available polyinosini+vaccine, simple vaccine.

The foregoing is only the preferred embodiment of the present invention; it is not limited to the present invention; for a person skilled in the art; the present invention can have various modifications and variations; all within the spirit and principles in the present invention; the any amendment made, equivalent replacement, improvement etc., should be included within protection scope of the present invention.

Claims

2. having the double stranded polynucleotide ε polylysine complex of immunoregulation effect as claimed in claim 1, wherein double stranded polynucleotide refers to the double stranded polynucleotide or derivatives thereof of anion, and source is natural extract or synthetic; Natural extract double stranded polynucleotide derives from the nucleic acid extractive of reovirus coe virus, comprises infections chicken cloacal bursa virus RNA, rotavirus RNA, ovine blue tongue viral RNA, African horse sickness virus RNA; The double stranded polynucleotide of synthetic comprises polyinosini; The final concentration of 1.0g 10g/L of double stranded polynucleotide.

3. having the double stranded polynucleotide ε polylysine complex of immunoregulation effect as claimed in claim 1, its cationic ε polylysine refers to the cationic ε amino homotype monomer-polymer containing 25 30 lysine residues; The cationic charge number that the preferred proportion of double stranded polynucleotide and ε polylysine is the anionic charge number that has of the phosphate radical of double stranded polynucleotide to be had with the amino of ε polylysine is than for 1:1; Its metal cation refers to Ca²⁺、Zn²⁺、Mg²⁺、Mn²⁺In one or more, and its metal ion is the form of soluble metallic salt, final concentration of 0.2mmol 4mmol/L; The preferred pH scope of its complex solution is 7.0 8.0.

4. double stranded polynucleotide as claimed in claim 3, is characterized in that preferred final concentration of 1.0g/L; The final concentration of 0.383g/L of corresponding ε polylysine; Corresponding metal cation is CaCl₂, final concentration of 0.4mmol/L; Pharmaceutical preparation solvent for use is the PBS of 0.01mol/L, pH=7.6.

5. the preparation method as claimed in claim 1 with the double stranded polynucleotide ε polylysine complex of immunoregulation effect, it is by the double stranded polynucleotide or derivatives thereof of anion and cation ε polylysine and the mutual compound of metal cation, and make complex, its operating procedure is as follows:

The double stranded polynucleotide or derivatives thereof PBS of anion is configured to the solution of concentration 1 20mg/ml, and degerming through the membrane filtration in 0.2 0.45 μm of apertures;

B. cation ε polylysine mother liquor:

Cation ε polylysine PBS is configured to the solution of concentration 1 20mg/ml, and degerming through the membrane filtration in 0.2 0.45 μm of apertures;

C. metal cation solution mother liquor:

Metal cation soluble-salt water for injection is configured to the solution that concentration is 0.1mol/L, and degerming through the membrane filtration in 0.2 0.45 μm of apertures;

D. prepared by double stranded polynucleotide ε polylysine complex: double stranded polynucleotide ε polylysine complex prepares rule: at 4 DEG C, first in the double stranded polynucleotide or derivatives thereof mother solution of anion, drip the ε polylysine mother solution of formula ratio, limit drips, limit is stirred, then the metal cation saline solution mother solution of formula ratio is dripped, limit drips, and limit stirring forms double stranded polynucleotide ε polylysine complex solution. Add PBS, regulate pH value to 7.0-8.0 simultaneously, and complex solution is sub-packed in sealing container by continuous stirring after 12 hours at 4 DEG C, boiling water bath 30 minutes, then in current, it is rapidly decreased to room temperature, makes finally aseptic double stranded polynucleotide ε polylysine complex solution through the membrane filtration in 0.2 0.45 μm of apertures is degerming.

6. there is the double stranded polynucleotide ε polylysine complex of immunoregulation effect as claimed in claim 1, it is characterized in that: by a kind of administration in following route of administration in the mankind or animal, this route of administration include intramuscular injection, lumbar injection, intravenous injection, subcutaneous injection, through respiratory tract suction, rectally, vagina administration, oral administration, nose administration, administration through eye, transdermal or intradermal administration.

7. one kind has the immunogenic composition causing to strengthen immunoreation with change immunoreation type action, it comprises the double stranded polynucleotide ε polylysine complex with immunoregulation effect described in claim 1 and antigen thing, and wherein antigen thing is artificial antigen, animal antigen, plant antigen, microbial antigen or tumor antigen.

8. have as claimed in claim 7 and cause the immunogenic composition strengthening immunoreation with changing immunoreation type action, wherein antigen thing is inactivated rabies virus antigen, and in every milliliter of said composition, inactivated rabies virus antigen valence is not less than 1 iu; Its every milliliter said composition double center chain polynucleotide ε polylysine complex, in contained double stranded polynucleotide, is not less than 0.7mg.

9. have as claimed in claim 7 and cause the preparation method strengthening immunoreation with the immunogenic composition changing immunoreation type action, be that double stranded polynucleotide ε polylysine complex and antigen thing are mutually mixed, and make compositions.

10. as claimed in claim 7 have cause strengthen immunoreation with change immunoreation type action immunogenic composition can by a kind of administration in following route of administration in the mankind or animal, this route of administration include intramuscular injection, lumbar injection, intravenous injection, subcutaneous injection, through respiratory tract suction, rectally, vagina administration, oral administration, nose administration, administration through eye, transdermal or intradermal administration.